ArticleBiomaterials translational2025
PBVHx-based microspheres for controlled BMP2 release and enhanced bone regeneration in a disuse osteoporosis mouse model.
Article in Biomaterials translational, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing biomedical innovation through composite material strategies.Biomaterials translational · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Addressing bone defects caused by degenerative diseases, trauma, and cancer through bone tissue engineering remains a significant global health challenge. The osteoinductive properties of bone morphogenetic protein-2 (BMP2) have become a key therapeutic strategy in bone regeneration. However, the development of biodegradable composites that ensure biocompatibility, stability, efficient BMP2 loading, and controlled release remains unresolved. In this study, we designed PBVHx/soy lecithin (SL)/BMP2 controlled-release microspheres (sB2PM) based on the biodegradable material poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) (PBVHx), incorporating SL to enable sustained BMP2 delivery and enhance capture. sB2PM microspheres exhibited uniform size (approximately 5 μm) and high BMP2 encapsulation efficiency (80.29%) compared to pure PBVHx-based microspheres (pPM). Due to PBVHx's biodegradability, BMP2 release was primarily degradation-driven, resulting in a controlled biphasic release profile. sB2PM achieved 62.79% cumulative BMP2 release over four weeks and continued to release BMP2 sustainably thereafter. Co-culturing sB2PM microspheres with human bone marrow-derived mesenchymal stem cells (hBMSCs) in a Transwell system showed enhanced cell proliferation, biocompatibility, and collagen secretion. Compared with pPM and B2PM, sB2PM significantly promoted osteogenic differentiation, increased alkaline phosphatase (ALP) activity, and upregulated osteogenic gene expression in hBMSCs, outperforming commercial hydroxyapatite microspheres. In a mouse hindlimb unloading osteoporosis model, micro computed tomography and histological evaluations confirmed that injectable sB2PM microspheres significantly enhanced bone regeneration, collagen secretion, and ALP and runt-related transcription factor 2 protein expression. This study highlights the potential of sB2PM microspheres with controlled BMP2 release for future bone regeneration therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.